Search Results - Po‐Lin Tseng

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy

    Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy by KC Chang, Y-Y Wu, Chien‐Hui Hung, SN Lu, Chi‐Ming Lee, King‐Wah Chiu, M-C Tsai, Po‐Lin Tseng, C-M Huang, Chung‐Lung Cho, Chien‐Jen Chen, T-H Hu

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect

    Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect by Po‐Lin Tseng, Wei-Hsuan Wu, Tsung‐Hui Hu, Chih‐Wei Chen, Hung-Chi Cheng, Chien‐Feng Li, Wen-Hui Tsai, Hui-Ju Tsai, Meng-Che Hsieh, Jiin-Haur Chuang, Wen‐Tsan Chang

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy

    A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination th... by K.-C. Chang, Chien‐Hui Hung, S.-N. Lu, J.-H. Wang, C.-M. Lee, Chia‐Hsiang Chen, Miaofen Yen, Shih‐Chieh Lin, Yi‐Hao Yen, Ming‐Chang Tsai, Po‐Lin Tseng, Tsung‐Hui Hu

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience

    Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience by Ming‐Chao Tsai, Chia‐Hsiang Chen, Po‐Lin Tseng, Chih‐Hsien Hung, King‐Wah Chiu, J.-H. Wang, Sheng‐Nan Lu, C.-M. Lee, Kuo‐Chin Chang, Yi‐Hao Yen, Ming‐Tsung Lin, Yeh‐Pin Chou, Tsung‐Hui Hu

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

    A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection by Kuo‐Chin Chang, Po‐Lin Tseng, Yi‐Ying Wu, Hung-Chao Hung, Chao-Min Huang, Sheng‐Nan Lu, Jing‐Houng Wang, Chuan–Mo Lee, Chien‐Hung Chen, Ming‐Chao Tsai, Yi‐Hao Yen, Ming‐Tsung Lin, Cheng‐Kun Wu, Chao‐Cheng Huang, Chien‐Jen Chen, Tsung‐Hui Hu

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: